Review Article
A Comprehensive Review on Pharmacotherapeutics of Herbal Bioenhancers
Table 7
Effect of piperine on pharmacokinetics of rifampicin, isoniazid, and pyrazinamide combination in human volunteers [
107,
108].
| Kinetic parameters | Formulation A | Formulation B | Rifampicin | Isoniazid | Pyrazinamide | Rifampicin** | Isoniazid** | Pyrazinamide** |
| (h) | 0.67 ± 0.008 | 0.64 ± 0.01 | 0.60 ± 0.03 | 0.40 ± 0.04 | 0.42 ± 0.04 | 0.37 ± 0.008 | (h) | 8.40 ± 0.06 | 7.90 ± 0.10 | 9.50 ± 0.14 | 11.1 ± 0.18 | 8.15 ± 0.26* | 11.0 ± 0.17 | (μg/mL) | 8.20 ± 0.46 | 2.56 ± 0.17 | 27.0 ± 2.0 | 17.6 ± 1.09 | 10.07 ± 0.90 | 40.0 ± 1.64 | AUC0–∞ (μg·h/mL) | 104.6 ± 4.38 | 41.0 ± 1.72 | 318.6 ± 8.05 | 143.95 ± 5.85 | 94.95 ± 3.98 | 435.41 ± 9.7 |
|
|
*Not significant (P > 0.05), **highly significant (P < 0.001). Formulation A: rifampicin—450 mg, isoniazid—300 mg, pyrazinamide—1500 mg. Formulation B: rifampicin—450 mg, isoniazid-300 mg, pyrazinamide—1500 mg, piperine—20 mg.
|